Sales Launch of COVID-19 (SARS-CoV-2) quantitative IgG ELISA!

New quantitative IgG-class antibody assay available to measure immune response and antibody levels against SARS-CoV-2 virus after vaccination!


The COVID-19 (SARS-CoV-2) quantitative IgG ELISA coded DECOV1901Q is a new immunoassay for the quantitative and qualitative detection of specific IgG-class antibodies to the spike protein of SARS-CoV -2.

It is designed to monitor antibody levels during and after a COVID-19 infection. Also it can be used for determination of antibody levels before and after a COVID-19 vaccination. Furthermore, the assay is intended to aid in the diagnosis of patients suspected of having COVID-19 disease or asymptomatic presentation of SARS-CoV-2.

To view the specific product site and package insert of our new COVID-19 (SARS-CoV-2) quantitative IgG ELISA coded DECOV1901Q, please click here.

Following characteristics come along with this assay:

  • CE-marked
  • Quantitative determination of IgG-class antibodies to the SARS-CoV-2 spike (S) protein
  • Trimeric SARS-CoV-2 Spike antigen
  • Calibrators correlate to WHO International Standard NIBSC code 20/136
  • Diagnostic specificity and sensitivity of 99.49% and 97% respectively (≥15 days post symptom onset)
  • Validated for human serum and plasma

If you need any further information, please contact us directly by sending an email to: